高级检索
当前位置: 首页 > 详情页

Prevalence of and risk factors for important comorbidities of systemic lupus erythematosus using data from a multicenter Chinese cohort registry: A cross-sectional study

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Peking Union Med Coll Hosp PUMCH, Chinese Acad Med Sci & Peking Union Med Coll, Minist Educ,Key Lab Rheumatol & Clin Immunol,Dept, State Key Lab Complex Severe & Rare Dis,Natl Clin, Shuaifuyuan 1, Beijing, Peoples R China [2]Hainan Gen Hosp, Dept Rheumatol, Haikou, Peoples R China [3]Cent South Univ, Xiangya Hosp, Dept Rheumatol, Changsha, Peoples R China [4]Nanchang Univ, Affiliated Hosp 2, Dept Rheumatol, Nanchang, Peoples R China [5]Guangxi Med Univ, Affiliated Hosp 1, Dept Rheumatol & Clin Immunol, Nanning, Peoples R China [6]Fourth Mil Med Univ, Xijing Hosp, Dept Clin Immunol & Rheumatol, Xian, Peoples R China [7]Inner Mongolia Med Coll, Affiliated Hosp, Dept Rheumatol, Hohhot, Peoples R China [8]Southern Med Univ, Nanfang Hosp, Dept Rheumatol & Immunol, Guangzhou, Peoples R China [9]First Peoples Hosp Yunnan Prov, Dept Rheumatol, Kunming, Peoples R China [10]Kunming Med Univ, Affiliated Hosp 1, Dept Rheumatol, Kunming, Peoples R China [11]Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Rheumatol, Hangzhou, Peoples R China
出处:
ISSN:

关键词: Cardiovascular disease Comorbidity Fragility fracture Risk factors Systemic lupus erythematosus

摘要:
ObjectivesPatients with systemic lupus erythematosus (SLE) are at high risk of cardiovascular disease (CVD), fragility fractures, and malignancies. However, data regarding these comorbidities among Chinese SLE patients are limited. We aimed to determine the prevalence of and risk factors for these three major comorbidities in a large cohort of Chinese SLE patients.MethodsIn this cross-sectional study, demographic, clinical, and common comorbidity profiles were obtained from the medical records of SLE patients enrolled in the Chinese SLE Treatment and Research group (CSTAR) registry. Univariate and multivariate logistic regression analyses were performed to identify possible risk factors related to these comorbidities.ResultsA total of 38,105 SLE patients were included (92.2% women). The median age at registration was 34.0 years (interquartile range, 27.0-46.0 years). The prevalence rates of the three important comorbidities at baseline were as follows: CVD, 1.9% (95% confidence interval [CI]: 1.8-2.0%); fragility fractures, 0.7% (95% CI: 0.6-0.8%); and malignancies, 0.7% (95% CI: 0.6-0.8%). In the multivariable-adjusted model, lupus anticoagulant, anticardiolipin antibody, anti-beta 2GP1 antibody, neuropsychiatric involvement, and hematological involvement were positively associated with CVD in SLE patients. Mucocutaneous manifestations, hyperimmunoglobulinemia, hypocomplementemia, anti-dsDNA, anti-Sm, and anti-nRNP/U1RNP antibody, and hydroxychloroquine therapy were negatively associated with CVD. The multivariate analysis revealed that age older than 50 years and hypocomplementemia were associated with fragility fractures and malignancies.ConclusionCVD, fragility fractures, and malignancies commonly occur in SLE patients. Patients with traditional and SLE-related factors should be more carefully monitored for these important comorbidities.Key Points center dot SLE patients have an increased risk of cardiovascular disease, fragility fractures, and malignancy. However, data regarding these comorbidities among Chinese SLE patients are limited.center dot Several associated risk factors for these three comorbidities of SLE were identified.Characteristics, symptom severity, and QOL differ in different age groups.center dot Lupus patients with traditional and SLE-related factors should be more carefully monitored for the presence of these comorbidities.ConclusionCVD, fragility fractures, and malignancies commonly occur in SLE patients. Patients with traditional and SLE-related factors should be more carefully monitored for these important comorbidities.Key Points center dot SLE patients have an increased risk of cardiovascular disease, fragility fractures, and malignancy. However, data regarding these comorbidities among Chinese SLE patients are limited.center dot Several associated risk factors for these three comorbidities of SLE were identified.Characteristics, symptom severity, and QOL differ in different age groups.center dot Lupus patients with traditional and SLE-related factors should be more carefully monitored for the presence of these comorbidities.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
最新[2025]版:
大类 | 3 区 医学
小类 | 4 区 风湿病学
JCR分区:
出版当年[2024]版:
Q2 RHEUMATOLOGY
最新[2024]版:
Q2 RHEUMATOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2023版]

第一作者:
第一作者机构: [1]Peking Union Med Coll Hosp PUMCH, Chinese Acad Med Sci & Peking Union Med Coll, Minist Educ,Key Lab Rheumatol & Clin Immunol,Dept, State Key Lab Complex Severe & Rare Dis,Natl Clin, Shuaifuyuan 1, Beijing, Peoples R China [11]Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Rheumatol, Hangzhou, Peoples R China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:91041 今日访问量:3 总访问量:767 更新日期:2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号 ICP备案:滇ICP备15003244号